Novartis (Syntometrine Drug) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Novartis (Syntometrine Drug) General Information

Description

An obstetric combination drug. The drug is used in the final stage of labor and the components are synthetically produced oxytocin, a human hormone produced in the hypothalamus and ergometrine, an alpha-adrenergic, dopaminergic and serotonin (5-HT2) receptor agonist.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Basel
  • Switzerland
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Acquirer
Alliance Pharma
Corporate Office
  • Basel
  • Switzerland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novartis (Syntometrine Drug) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Novartis (Syntometrine Drug)‘s full profile, request access.

Request a free trial

Novartis (Syntometrine Drug) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Novartis (Syntometrine Drug)‘s full profile, request access.

Request a free trial

Novartis (Syntometrine Drug) FAQs

  • Where is Novartis (Syntometrine Drug) headquartered?

    Novartis (Syntometrine Drug) is headquartered in Basel, Switzerland.

  • What industry is Novartis (Syntometrine Drug) in?

    Novartis (Syntometrine Drug)’s primary industry is Buildings and Property.

  • Is Novartis (Syntometrine Drug) a private or public company?

    Novartis (Syntometrine Drug) is a Private company.

  • What is the current valuation of Novartis (Syntometrine Drug)?

    The current valuation of Novartis (Syntometrine Drug) is .

  • What is Novartis (Syntometrine Drug)’s current revenue?

    The current revenue for Novartis (Syntometrine Drug) is .

  • Who are Novartis (Syntometrine Drug)’s investors?

    Novartis has invested in Novartis (Syntometrine Drug).

  • When was Novartis (Syntometrine Drug) acquired?

    Novartis (Syntometrine Drug) was acquired on 06-Jun-2013.

  • Who acquired Novartis (Syntometrine Drug)?

    Novartis (Syntometrine Drug) was acquired by Alliance Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »